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TREK-1 is a two-pore-domain background potassium
channel expressed throughout the central nervous system.
It is opened by polyunsaturated fatty acids and lysopho-
spholipids. It is inhibited by neurotransmitters that pro-
duce an increase in intracellular cAMP and by those that
activate the Gq protein pathway. TREK-1 is also activated
by volatile anesthetics and has been suggested to be an
important target in the action of these drugs. Using mice
with a disrupted TREK-1 gene, we now show that TREK-1
has an important role in neuroprotection against epilepsy
and brain and spinal chord ischemia. Trek1/ mice dis-
play an increased sensitivity to ischemia and epilepsy.
Neuroprotection by polyunsaturated fatty acids, which
is impressive in Trek1þ /þ mice, disappears in Trek1/
mice indicating a central role of TREK-1 in this process.
Trek1/ mice are also resistant to anesthesia by volatile
anesthetics. TREK-1 emerges as a potential innovative
target for developing new therapeutic agents for neurology
and anesthesiology.
The EMBO Journal advance online publication, 3 June 2004;
doi:10.1038/sj.emboj.7600234
Subject Categories: neuroscience; molecular biology of
disease
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Introduction
Two-pore-domain potassium channels (K2P channels) form a
novel class of Kþ channels identified in various types of
neurons (Kim et al, 1995; Wei et al, 1996; Lesage and
Lazdunski, 2000; Talley et al, 2003). They are open at
membrane potentials across the physiological range and are
therefore likely to contribute to the background or leak
currents that help set the resting membrane potential and
oppose depolarizing influences. They are key components in
shaping the characteristics of neuronal excitability. TREK-1
(Fink et al, 1996) is expressed throughout the central nervous
system (Fink et al, 1996; Lauritzen et al, 2000; Maingret et al,
2000b; Hervieu et al, 2001; Talley et al, 2001) and is an
important member of this family. It is the probable mamma-
lian homolog of the Aplysia S-type Kþ channel (Siegelbaum
et al, 1982; Patel et al, 1998), a channel involved in simple
forms of learning and memory. TREK-1 is activated by
membrane stretch and intracellular acidification (Patel et al,
1998; Maingret et al, 1999b). TREK-1 is opened by arachido-
nic acid and other polyunsaturated fatty acids (PUFAs) as
well as lysophospholipids (LPLs) (Patel et al, 1998; Maingret
et al, 2000b). On the other hand, PUFAs and LPLs are potent
protective agents against forebrain ischemia and seizures,
and it has been proposed that this effect results, at least in
part, from their action on TREK channels (Lauritzen et al,
2000; Blondeau et al, 2001, 2002). TREK-1 probably has a
central role in the control of excitability by a variety of
neurotransmitters. TREK-1 is potently inhibited by neuro-
transmitters that produce an increase in intracellular cAMP
(Patel et al, 1998) and also by those that activate the Gq
protein pathway (Lesage et al, 2000; Chemin et al, 2003). The
inhibition of TREK channels by glutamate via the activation
of group I Gq-coupled metabotropic glutamate receptors
requires PTX-insensitive G proteins coupled to phospholipase
C (Chemin et al, 2003). TREK-1 is also activated by volatile
anesthetics and suggested to be a target in the action of these
drugs (Patel et al, 1999). This paper definitively shows that
TREK-1 plays a major role in the PUFAs/LPLs-induced neu-
roprotection against epilepsy and ischemia and that TREK-1-
deficient mice display resistance to anesthesia.
Results
Generation and characterization of TREK-1 null mice
The TREK-1 gene of mice was disrupted through homologous
recombination using a Cre/loxp-based strategy (Figure 1A).
The CRE-mediated excision of exon 3 led to the deletion of the
first transmembrane domain of the TREK-1 channel.
Heterozygous matings produced offspring with normal
Mendelian ratios (Figure 1B and C). Homozygous (Trek1/)
mutant mice were healthy, fertile and did not display any
visible morphological differences. PCR amplification of testi-
cular cDNA (a tissue where TREK-1 is abundant; Hervieu
et al, 2001; Talley et al, 2001) showed that the null mutant
only expressed a truncated transcript (Figure 1D).
Sequencing of this transcript confirmed that it results from
the deletion of the 311 nucleotides of the targeted exon
(Figure 1D). The brain morphology of Trek1/ mice ap-
peared normal. In brain regions known to express the KCNK2
gene, no TREK-1 messenger RNA was detected by in situ
hybridization using a probe recognizing the 30-end of the
mRNA (Figure 1E). The absence of the TREK-1 protein in null
mutants was confirmed by the lack of immunoreactivity to
specific anti-TREK-1 antibody (Maingret et al, 2000a) in brain
areas such as the cortex or the hippocampus where it is
highly expressed (Figure 1F).Received: 10 March 2004; accepted: 19 April 2004
*Corresponding author. Institut de Pharmacologie Mole´culaire et
Cellulaire, CNRS-UMR 6097, Institut Paul Hamel, 660 Route des
Lucioles, Sophia-Antipolis, 06560 Valbonne, France.
Tel.: þ 33 493 957702/03; Fax: þ 33 493 957704;
E-mail: ipmc@ipmc.cnrs.fr
1These authors contributed equally to this work
The EMBO Journal (2004), 1–12 | & 2004 European Molecular Biology Organization | All Rights Reserved 0261-4189/04
www.embojournal.org
&2004 European Molecular Biology Organization The EMBO Journal
 
EMBO
 
THE
JOURNAL
1
Figure 1 Disruption of the KCNK2 gene. (A) Targeting vector (c¼ loxp), native (WT) and recombined floxed (Flox) alleles. External probes
used to characterize homologous recombination are designated as P1 and P2. Arrowheads (1–3) display locations of the primers used for PCR
analysis of the different products. Double-headed arrows indicate the expected size of restriction fragments for Southern analysis (bg¼BglII;
b¼BamHI; e¼EcoRI). (B) Southern blot analysis of EcoRI- and BamHI-digested tail DNA from wild-type (þ /þ ), heterozygous (þ /) or
homozygous (/) KCNK2 mice probed with P1 and P2, respectively. (C) PCR amplification from tail genomic DNA. (D) PCR amplification
from þ /þ , þ / and / mouse testis cDNA with primers surrounding the deletion. (E) In situ hybridization analysis shows the lack of
mRNA expression in Trek/ mouse brain on X-ray films. (F) Immunocytochemical TREK-1 staining in neocortex (Cx) and hippocampal CA3
subfield sections using a specific a-TREK-1 antibody (Lauritzen et al, 2000).
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The TREK-1 mutation did not interfere with the mRNA
expression in brain and cerebellum of other K2P channels and
of the GABAa6 subunit whose deletion causes an increased
expression of TASK-1, another K2P channel (Brickley et al,
2001) (Figure 2A). There was no compensatory upregulation
of genes for other neuronal K2P channels such as TWIK-1,
TREK-2, TRAAK, TASK-1, TASK-3 or the GABAa6 subunit in
Trek1/ mice (Po0.01).
Primary behavioral testings (see Supplementary Materials
and methods) showed that the TREK-1-deficient mice did
not display any abnormal phenotype in appearance
(Figure 2B). There was no difference in skin color, body
tone or body weight. Trek1/ mice did not display any
abnormalities in body position, respiration or spontaneous
activity. Stereotypies or tremor were not observed. There was
no difference in frequency and volume of defecation or
urination. Locomotor activity of the Trek1/ mutant was
not different from Trek1þ /þ control in the open field test
as well as in the rotarod. No difference was seen in the
touch escape response or in the positional passivity test.
Recordings of reflexes and autonomic functions did not
show any significant differences. Scorings were comparable
in the visual placing test, grip strength, corneal and
pinna reflex and in the righting reflex. No significant differ-
ence was seen between Trek1þ /þ and Trek1/ mice in the
object recognition test.
For comparative purpose, we have also deleted the TRAAK
gene (see Supplementary Materials and methods and
Supplementary Figure 1) to be able to evaluate the respective
properties of Trek1/ and Traak/ mice. The TRAAK
channel is closely related to the TREK-1 channel. Like
TREK-1, it is a background outward rectifier Kþ channel,
opened by membrane stretch, cell swelling and activated by
PUFAs and LPLs. However, unlike TREK-1, the TRAAK chan-
nel is not activated by intracellular acidification (Maingret
et al, 1999b) nor volatile anesthetics (Patel et al, 1999) and
not inhibited by neurotransmitters that increase cAMP via
a protein kinase A-dependent phosphorylation process (Fink
Figure 2 Characterization of TREK-1 null mice. (A) Relative expression of TREK-1, TREK-2, TRAAK, TASK-1, TASK-3 and GABAa6 mRNA
levels in brain and cerebellum from Trek1/ and Trek1þ /þ mice. Mean levels of gene expression, normalized to cyclophilin D, are displayed
in arbitrary units on the vertical axis (n¼ 3 mice, Po0.01, Student’s t-test). (B) Primary behavioral test battery showing the lack of abnormal
phenotype in TREK-1-deficient mice. Results are expressed as mean7s.e.m. Statistical significance was set at Po0.05 (Student’s t-test or a
Mann–Whitney test).
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et al, 1998; Maingret et al, 1999a) or by those that activate the
Gq protein pathway (Chemin et al, 2003).
Electrophysiological recordings
To test whether TREK-1 currents could be recorded in neu-
rons from wild-type mice and were absent in neurons from
TREK-1 null mice, we performed patch clamp recordings
in striatal neurons in culture. These neurons were chosen
because they strongly express TREK-1 but not TREK-2 or
TRAAK channels (Hervieu et al, 2001; Talley et al, 2001), two
K2P channels that are also activated by membrane stretch,
PUFAs and LPLs (Lesage and Lazdunski, 2000; Lesage et al,
2000; Patel and Honore´, 2001). In the striatum, the primary
type accounting for 85% of the neurons is the GABAergic
medium-size spiny neuron (Kita and Kitai, 1988). Using an
antibody against GABA, we have checked that most neurons
in our culture were indeed GABAergic (data not shown). The
resting membrane potential of the striatal neurons from
Trek1þ /þ and Trek1/ mice was not significantly different
(Student’s t-test, P¼ 0.0586) with 47.271.6 mV (n¼ 30)
and 51.577.5 mV (n¼ 26), respectively. Neurons with rest-
ing membrane potential less negative than 30 mV were
discarded. Using the inside-out configuration and in the
presence of Kþ channels blockers (TEA, 4-AP and gliben-
clamide), a native TREK-1-like current was regularly recorded
in cultures from wild-type mice. This current was reversibly
activated by 10 mM arachidonate (AA) (Figure 3A) and by
internal acidification (Figure 3B), as previously described
(Maingret et al, 1999b, 2000b). The conductance was
55.870.9 pS at þ 50 mV (n¼ 6), which is close to the con-
ductance of the cloned TREK-1 (Patel et al, 1998). The out-
wardly rectifying current reversed around the potassium
equilibrium potential (Figure 3C). Like TREK-1 (Patel et al,
1998), the native current was also activated by membrane
stretch (Figure 3D). The effect of volatile anesthetics was also
studied on the TREK-like current recorded in striatal cultures
from wild-type mice (Figure 3E, inset) and in TREK-1-trans-
fected COS cells (Supplementary Figure 2A and B). Halothane
in striatal neurons (Figure 3E, inset) as well as halothane and
sevoflurane in COS cells (Supplementary Figure 2A and B)
highly stimulated a TREK-1 channel activity. The loss of
functional TREK-1 channels in TREK-1 null mutants was
demonstrated by outside-out patch clamp recordings in stria-
tal neurons. Figure 3E and F shows that in the presence of
TEA and 4-AP to block voltage-dependent Kþ channels, there
was no expression of basal current in wild-type neurons and
in null mutants. Upon perfusion with the TREK-1 activator
AA (20mM), a robust TREK-1-like current was recorded in
Trek1þ /þ neurons, whereas no significant variation was
observed in Trek1/ neurons. This electrophysiological ana-
lysis confirmed (i) that the TREK-1 deletion had taken place
and (ii) that there was no compensatory upregulation of
genes for other neuronal K2P channels.
Role for the TREK-1 channel in the control
of epileptogenesis
The high level of TREK-1 channel expression in the cortex
and thalamic nuclei and its colocalization on GABAergic
cortical and hippocampal interneurons, which are inhibitory
to pyramidal cell activity (Hervieu et al, 2001; Talley et al,
2001), suggest a possible involvement of the TREK-1 channel
in the control of epileptic seizures. To analyze the seizure
susceptibility of Trek-1-deficient mice, we used the response
to kainic acid (KA, an agonist of glutamate receptor) and to
pentylenetetrazol (PTZ, a GABAA receptor antagonist), as an
overall index of neuronal network excitability. Trek1þ /þ and
Trek1/ mice were injected intraperitoneally with epilepto-
genic doses of KA (22 mg/kg) or PTZ (40–55 mg/kg) and the
degree of seizures was scored (Tsirka et al, 1995). Trek1/
mice were much more vulnerable to KA-induced seizures
than Trek1þ /þ mice as assessed by either seizure score or
mortality rate (Figure 4A). More than 75% of the mutant
mice died within 3 days of KA administration, compared with
3% of Trek1þ /þ mice, and the average maximum intensity
of seizures observed in Trek1/ mice increased by 33%. A
comparison of electroencephalogram (EEG) patterns in the
hippocampus of Trek1þ /þ and Trek1/ mice is shown in
Figure 4F. A spectral analysis of EEG activity shows that
45 min following KA treatment (22 mg/kg), Trek1/ mice
developed generalized convulsive seizures with the appear-
ance of bilateral spike-wave discharges with spike frequen-
cies and amplitudes higher than in Trek1þ /þ mice (Figure
5A and B).
Figure 3 Patch clamp recordings in striatal neurons from Trek1þ /þ
and Trek1/ mice. (A) Activation of the TREK-like current by
10 mM AA. (B) Activation of the TREK-like current by internal
acidification to pH 5.5. Currents in (A, B) were recorded in in-
side-out configuration at 0 mV. (C) Single channel currents recorded
as in (A) at various potentials as indicated. (D) Activation by
membrane stretch recorded as in (A) at various negative pressures
as indicated. (E) Typical TREK-like current recorded in outside-out
configuration before (control) and after activation by 10 mM AA in
striatal neurons from wild-type mice (WT). Values are average of
two consecutive current traces elicited with voltage ramps starting
from 0 mV down to 120 mV, from a holding potential of 0 mV.
Inset: Effect of 2 mM halothane (hal) on TREK-like activity recorded
at 0 mV in outside-out configuration. (F) Same recordings in
neurons from TREK-1 knockout mice (KO).
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Trek1/ mice also showed an increased sensitivity to
PTZ-induced seizures (Figure 4B). Unlike the slow progres-
sion of motor symptoms observed in the KA-induced sei-
zures, PTZ induced abrupt general tonic–clonic seizures
within 5 min of injection. At a dose of 55 mg/kg, more than
90% of Trek1/ mice died from continuous tonic–clonic
convulsions, whereas 60% of Trek1þ /þ mice survived
(Figure 4B).
Activation of c-fos, in regions susceptible to kainate injec-
tion, is routinely used as a biochemical marker of neuronal
excitability (Smeyne et al, 1992). The expression of the c-fos
protein was drastically enhanced in Trek1/ mice compared
to Trek1þ /þ mice, particularly in CA3 subfield at 120 min
after KA injection (Figure 4E).
A comparative study was carried out with the TRAAK
channel. TRAAK-deficient mice did not display an increased
sensitivity to epilepsy (Figures 4C, D and G and 5C). Taken
together, all these results show that, unlike TRAAK null mice,
TREK-1-deficient mice are hypersensitive to kainate and PTZ-
induced seizures and point to TREK-1 as a key target for
epileptogenesis.
TREK-1 channel in brain and spinal chord ischemia and
its major role in the neuroprotection provided by PUFAs
and LPLs
Linolenic acid (LIN) or lysophosphatidylcholine (LPC) at a
dose of 500 nmol/kg injected 30 min before the KA adminis-
tration induced a potent decrease of the seizure activity in
Trek1þ /þ mice but had no effect in Trek1/ mice (Figure 6A
and B). The seizure score or the mortality rate shows that
LIN- or LPC-injected Trek1þ /þ mice were much less vulner-
able to KA-induced seizures than vehicle-injected Trek1þ /þ
mice, while LIN- or LPC-injected Trek1/ mice were not
protected (Figure 6A). More than 78% of the mutant mice
treated with LIN or LPC died within 3 days of KA22 adminis-
tration, compared with 3% of LIN- or LPC-injected Trek1þ /þ
mice, and the average maximum intensity of seizures ob-
served in treated Trek1/ mice increased by 38%. EEG
Figure 4 Increased susceptibility to epileptic agents in TREK-1-deficient mice. (A, B) Seizure behavior and mortality rate in wild-type
and mutant TREK-1 mice after KA (A) or PTZ injection (B). (C, D) Seizure behavior and mortality rate in wild-type and mutant TRAAK mice
after KA (C) or PTZ (D) injection. Seizures were scored for 2 h after intraperitoneal injection with KA (22–28 mg/kg) or PTZ (40–55 mg/kg).
Seizures were ranked as follows: 1, immobility; 2, myoclonic jerks of the neck and head with brief twitching movements; 3, unilateral clonic
activity; 4, bilateral forelimb tonic and clonic activity; 5, generalized tonic–clonic activity with loss of postural tone including death
from continuous convulsions. Values represent mean7s.e.m. of the maximum seizure intensity recorded for each mouse (n¼ 20 per
genotype). *Significantly different from vehicle-treated wild type (KA treatment 22 mg/kg), **Po0.001, ***Po0.0001, ANOVA followed by
Tukey’s multiple comparison test. (E) Increased expression of c-fos protein in CA3 pyramidal neurons in Trek1/ mice 120 min after KA
treatment (22 mg/kg). (F) EEG following KA (22 mg/kg) showing the increased KA susceptibility of Trek1/ mice as compared to Traak/
mice (G) (n¼ 10 per genotype).
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patterns in the hippocampus of Trek1þ /þ and Trek1/ mice
treated with LIN (Figure 6B) and their spectral analysis of
EEG activity (Figure 5B) confirm the lack of efficiency of LIN
treatment in null mutant mice. The same protocol applied to
TRAAK mice showed no difference in the neuroprotective
effect of LIN or LPC between Traakþ /þ and Traak/ mice
(data not shown). This strongly suggests that the antiepileptic
effect of PUFAs or LPLs is directly related to the activation
of the TREK-1 channel.
Another important cause of neuronal damage is ischemia.
Trek1þ /þ and Trek1/ mice were submitted to a transient
bilateral occlusion of common carotid arteries (CCAs) during
systemic hypotension (mean arterial blood pressure (MABP)
3073 mmHg) maintained for 30 min. Trek1þ /þ mice pre-
sented no sign of hyperexcitability in the days following a
30 min period of ischemia. In contrast, most of the knockout
mice developed seizures of progressive severity during the
same time of reperfusion. More than 70% of Trek1/ mice
died in the 3 days after ischemia compared with 34% of
Trek1þ /þ mice (Figure 6C; Po0.001). LIN or LPC
(500 nmol/kg) injected 30 min before the induction of global
ischemia had no effect in Trek1/ mice, while it protected the
Trek1þ /þ mice against neuronal death and significantly
increased their survival (Figure 6C). This observation
strongly suggests that the neuroprotective effect of PUFAs
or LPLs against global ischemia is directly related to the
activation of the TREK-1 channel. The specificity of the
TREK-1 channel in neuroprotection against ischemic injury
is strengthened by results obtained with TRAAK-deficient
mice, which did not display an increased sensitivity to
ischemia (Figure 6C).
We also analyzed the role of TREK-1 in spinal cord
ischemia. It is a devastating complication with resulting
paraplegia, observed after repair of thoracic or abdominal
Figure 5 Spectral profiles of EEG recordings following KA (22 mg/kg) injection in Trek and Traak mice. (A) Increased KA susceptibility of
Trek1/ mice. (B) No anticonvulsive effect of LIN injection in Trek1/ mice. (C) No difference in KA susceptibility between vehicle-treated
Traak/ (KO) and Traakþ /þ (WT) mice. Spectral profiles of EEG recordings (n¼ 10 per genotype and treatment) are shown 15 and 45 min
following KA injection in vehicle-treated Trek1þ /þ and Trek1/ mice and 45 min following KA injection in LIN (500 nmol/kg)-treated
Trek1þ /þ and Trek1/ mice. Spectral profiles of EEG recordings in vehicle-treated Traak mice are shown 45 min following KA injection.
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aortic aneurysms or dissection (Kouchoukos and Dougenis,
1997). Combined occlusion of the aortic arch and left sub-
clavian artery was performed to induce spinal cord ischemia
in mice (Lang-Lazdunski et al, 2000). Values of mean femoral
arterial blood pressure (MABP) recorded for 5 h throughout
the procedure did not differ significantly between Trek1þ /þ
and Trek1/ mice (Table Ia). The susceptibility to spinal
cord ischemia was much higher in null allele mice. A total of
75% of Trek1/ mice died within the first 3 h following
10 min ischemia compared with 14% of Trek1þ /þ mice up to
24 h after the procedure (Table Ib; Po0.001). All surviving
Trek1þ /þ mice recovered without any neurological deficit
and failed to develop any form of neurological deficit during
the subsequent 48 h. In contrast, surviving Trek1/ mice
developed severe hind limb paralysis at the onset of reperfu-
sion. They remained paralyzed during the first hours of
reperfusion and retained deficits in motor function during
the subsequent 48 h (Table Ib). Within 5 min following aortic
crossclamping, Trek1/ mice had vesical relaxation with
urination, which did not occur in Trek1þ /þ mice, further
indicating a lower tolerance to spinal cord ischemia.
Autopsies of Trek1/ mice did not reveal any severe
abnormality in heart, lungs or major vessels.
TREK-1 channel in the mechanism of action of volatile
anesthetics in vivo
Another interesting property of the TREK-1 channel concerns
its sensitivity to activation by general volatile anesthetics
(Patel et al, 1999), and we hypothesized (Patel et al, 1999)
that TREK-1 might be involved in the mechanism of action of
these agents. The comparative sensitivity to different volatile
anesthetics of Trek1þ /þ and Trek1/ mice was assessed by
comparing the onset of anesthetic action, the loss of righting
reflex (LORR) and the inspired minimum alveolar anesthetic
concentration (MAC) values for each anesthetic in both. MAC
is the minimum steady-state alveolar concentration of an
inhalational anesthetic required to suppress a strong motor
reaction to the noxious stimulus of tail-clamping in 50% of
mice (Quasha et al, 1980). Figure 7A shows that knockout
mice had a decreased sensitivity to chloroform and halo-
thane, which are the most potent activators of the TREK-1
channel in vitro (Patel et al, 1999). Interestingly, the same
Figure 6 Increased vulnerability of TREK-1-deficient mice to ischemia and loss of the neuroprotective effect of LIN and LPC in Trek1/
mice. (A) Effect of LIN or LPC injection (500 nmol/kg) 10 min before KA treatment. (B) EEG recordings (15 and 45 min after KA treatment) in
Trek1þ /þ and Trek1/ mice with or without LIN (500 nmol/kg). (C) Increased mortality rate in vehicle (Veh)-, LIN- or LPC-treated Trek1/
mice following 30 min global ischemia (n¼ 20 per genotype). LIN and LPC were injected at a concentration of 500 nmol/kg 30 min before
ischemia. *Significantly different from vehicle-treated wild type (KA treatment 22 mg/kg), #significantly different from vehicle-treated wild type
(KA treatment 28 mg/kg), **Po0.001, ***Po0.0001, ###Po0.0001, ANOVA followed by Tukey’s multiple comparison test.
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type of results was obtained with sevoflurane and desflurane
(Figure 7B), the most widely used agents in clinical anes-
thesia as well as isoflurane (Supplementary Figure 2C). The
period of time necessary for the induction of anesthesia was
longer, the concentrations required for LORR lower and the
partial pressures of all anesthetics tested (i.e. MAC) were
higher in Trek1/ mice. There was no significant difference
in the respiratory rate between either genotype before induc-
tion of anesthesia and at the MAC value (Table II). In contrast
with volatile anesthetics, no difference was seen between
Trek1þ /þ and Trek1/ mice upon injection of the barbitu-
rate pentobarbital (Figure 7C), which produces anesthesia by
acting on different GABAA receptor subunits (Yamakura et al,
2001) and in vitro it has no effect on TREK-1 channel activity
(Figure 7C), unlike halothane and sevoflurane (Supple-
mentary Figure 2A and B). Pentobarbital did not affect the
latency or the duration of LORR (Figure 7C) in null mutants.
This latter result supports the idea that the differences
observed are specific to volatile anesthetics and related to
the TREK-1 channel.
Discussion
Potassium channels play a major role in the control of Kþ
homeostasis and in physiological and pathological functions
that are associated with modifications of the electrical mem-
brane potential. Many subtypes of Kþ channels have been
cloned in the past decades (Salkoff et al, 1992; Jan and Jan,
1997; Pongs, 1999; Kurachi et al, 1999). The mammalian two-
pore-domain Kþ channel family (Lesage and Lazdunski,
2000; Patel and Honore´, 2001; Lesage, 2003), and particularly
the TREK-1 channel, has been proposed to play a key role in
brain and spinal chord injuries (Lauritzen et al, 2000;
Blondeau et al, 2002; Lang-Lazdunski et al, 2003). The lipid
and mechano-gated TREK-1 channel is closely related to
pathophysiological conditions, such as ischemia and epi-
lepsy. It is activated by arachidonic acid and other PUFAs,
LPLs, cell volume expansion and internal acidosis. During the
process of ischemia, arachidonic acid is released from the
plasma and intracellular pH is decreased. These condition
changes could potently activate the lipid-sensitive mechano-
gated K2P channels, an activation that would occur to protect
the neuronal cell against excessive and deleterious neuronal
excitability and Ca2þ entry. On the other hand, the TREK-1
channel is inhibited by the activation of group I metabotropic
glutamate receptors, known to be involved in brain disorders,
including ischemia, epilepsy and neurodegenerative disor-
ders (Bockaert et al, 1993; Bordi and Ugolini, 1999; Fagni et al,
2000). Group I metabotropic glutamate receptor antagonists
are neuroprotectors, while agonists amplify the excitotoxic
neuronal degeneration induced by glutamate (Nicoletti et al,
1996; Gasparini et al, 2002). In fact, injections of PUFAs and
LPLs protect against brain and spinal chord ischemia as well
as epileptic seizures (Lauritzen et al, 2000; Blondeau et al,
2001, 2002; Lang-Lazdunski et al, 2003). Riluzole, another
activator of TREK-1 channel (Duprat et al, 2000), is also
neuroprotective against ischemia (Pratt et al, 1992; Ettaiche
et al, 1999; Lang-Lazdunski et al, 1999). Although the open-
ing of lipid-sensitive mechano-gated K2P channels has been
presumed to be the significant factor in neuroprotection, the
lack of specific blockers did not allow until now a direct
demonstration of this property. Using mice with disrupted
TREK-1 and TRAAK genes, the present study provides evi-
dence for a major role of the TREK-1 channel in surviving
excessive neuronal excitability and in resistance to forebrain
and spinal cord ischemia. The absence of an increased
sensitivity to ischemia and epilepsy in Traak/ mice demon-
strates that the extreme vulnerability of Trek1/ mice is not
a nonspecific effect due to the lack of an important Kþ
channel on neuronal excitability. Consequently, the TREK-1
channel can be considered to play a key role in the regulation
of neuronal excitability. The high expression of the TREK-1
Table I Comparison of susceptibility to spinal cord ischemia in wild-type and TREK-1-deficient mice
(a) Physiological variables
Genotype Mean arterial blood pressure (mmHg) Rectal temperature (1C)
Preischemia Ischemia Reperfusion Preischemia Ischemia Reperfusion
Trek1+/+ 71.973.3 16.176.2 67.474.2 37.570.4 37.370.5 37.670.3
Trek1/ 73.272.9 17.272.4 69.773.8 37.370.3 37.270.3 37.470.2
(b) Number of mice with their neurologic status (MSDI) and death rate at the onset of reperfusion and 1, 3 and 24 h after ischemia
MSDI
Time after ischemia (h) Genotype 0 1 2 3 4 5 6 Death
0 Trek1+/+ 0 7 0 0 0 0 0 0
Trek1/* 0 0 0 0 0 0 8 0
1 Trek1+/+ 1 6 0 0 0 0 0 0
Trek1/* 0 0 0 0 0 1 3 4
3 Trek1+/+ 7 0 0 0 0 0 0 0
Trek1/* 0 0 0 1 1 0 0 2
24 Trek1+/+ 6 0 0 0 0 0 0 1
Trek1/* 0 2 0 0 0 0 0 0
The neurologic score involved a six-point scale (0 (normal function) to 6 (severe paraplegia); Lang-Lazdunski et al, 2000). Motor sensory
deficit indices (MSDIs) were analyzed with Kruskal–Wallis test followed by Mann–Whitney U-test when significant. *Po0.05 versus wild-type
mice.
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protein both pre- and postsynaptically in the cortex and
thalamic nuclei is consistent with a potential role for this
channel in prevention of epileptic seizures. The high levels of
TREK-1 expression in the hippocampus, a structure suscep-
tible to damage during ischemia, and its modulation by
neurotransmitter receptor activation are supplementary argu-
ments for a major role of this channel in the control of
excitotoxicity. Its activation in the neurons would be expected
to hyperpolarize synaptic terminals, decreasing glutamate
release and/or producing a postsynaptic hyperpolarization,
which would favor the blockade of the NMDA receptor-
associated channel by Mg2þ and also counterbalance gluta-
mate-induced depolarization on other types of ionotropic
glutamate receptors (Lauritzen et al, 2000). Without exclud-
ing a localization of the TREK-1 protein in glutamatergic
neurons (Lauritzen et al, 2000), the TREK-1 channel has
been described to be colocalized in GABAergic interneurons,
specifically from striatum (this work), cerebellum, cortex and
hippocampus (Hervieu et al, 2001). The phenotype of ex-
treme vulnerability of TREK-1 null mutants against epilepsy
and ischemia is consistent with the absence of TREK-1
channel in GABAergic interneurons, known to serve inhibi-
tory functions in CNS and be involved in ischemic and
epileptic disorders (Treiman, 2001; Wang, 2003). In the light
of the role of TREK-1 channels in setting resting membrane
potential, this is suggestive that TREK-1 may set the mem-
brane potential of interneurons and thereby contribute to
their often distinctive neurophysiological properties.
The beneficial effects of PUFAs on human health have long
been advocated (Leaf and Kang, 1996; Nair et al, 1997; Leaf
et al, 1999; Nordoy, 1999; Stoll et al, 1999) and indeed the
effects of PUFAs on neuroprotection against epilepsy and
ischemic paradigms in animals are spectacular (Lauritzen
et al, 2000; Lang-Lazdunski et al, 2003). The results pre-
sented here strengthen the idea that neuroprotection induced
by PUFAs (and LPLs) against seizures and ischemia is related
to their action on the TREK-1 channel since this neuroprotec-
tion disappears in Trek1/ mice and open the way for a
novel neuroprotective strategy.
The possibility that a significant part of the effects of
general anesthetics might result from potassium channel
activation and especially K2P channels has been previously
suggested (Patel et al, 1999). This work definitively shows
that the deletion of the TREK-1 gene induces a resistance to
volatile anesthetics. This resistance is actually the greatest
found for any ion channel knockout tested, including knock-
outs of GABAA receptors (Campagna et al, 2003), also be-
lieved to be potential targets of volatile anesthetics. One
might of course wonder why the deletion of TREK-1 does
not completely abolish sensitivity to volatile anesthetics. An
important reason is that volatile anesthetics such as halo-
thane, desflurane and sevoflurane also activate other K2P
channels such as TREK-2 and TASK channels (Patel et al,
1999; Lesage et al, 2000), which are still expressed in the
Trek1/ mice. It will be important in the future to analyze
multiple K2P channel knockouts, which would then be ex-
pected to display extreme resistance to volatile anesthetics.
Further experiments using selective Cre mice to abolish
specifically the gene in a tissue or a cell type will also permit
a more detailed analysis of the cellular mechanisms that
underlie the behavioral responses.
Figure 7 Effects of different anesthetics on LORR and MAC in
Trek1þ /þ and Trek1/ mice. LORR measurements after inhalation
of volatile anesthetics. Latency to LORR is defined as the period of
time (s) from inhalation to the LORR. Concentration for LORR
corresponds to average concentrations of volatile anesthetics (A)
chloroform and halothane and (B) sevoflurane and desflurane for
the recovery from LORR. (C) LORR measurements (latency and
duration of LORR expressed in minutes) after pentobarbital injec-
tion (30 mg/kg). Lack of effect of pentobarbital (2.4 mM) on TREK-1
channel expressed in transfected COS cells. I–V curves in steady-
state control condition and after a 5 min application of pentobarbital
(2.4 mM). I–V curve was elicited by a voltage ramp (1 s duration
from 130 to þ 100 mV). Data represent mean7s.e.m. (n¼ 20 per
genotype and anesthetic agent). Statistical significance (Student’s
t-test): **Po0.001, ***Po0.0001. Logistic regression probability of
no movement fitted for volatile anesthetic concentrations. MAC and
its 95% confidence interval (horizontal line) are shown on each
graph.
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In conclusion, this work provides evidence for a major
involvement of the TREK-1 channel in the control of the
neuronal excitability and neuroprotective effects induced by
PUFAs and LPLs against ischemia and epileptic seizures.
TREK-1 appears to be an innovative target for the develop-
ment of novel therapeutic neuroprotective strategies for brain
pathologies.
Materials and methods
All experiments were conducted according to the policies on the
care and use of laboratory animals of the Society of Neurosciences.
Generation of TREK-1-deficient mice
Trek-1 genomic clones were isolated from a 129 mouse genomic
library by using a TREK-1 cDNA probe and subcloned into
pBluescript SK (Stratagene). The floxed targeting vector was
generated from a 7.5 kb BglII/EcoRI restriction fragment containing
exons 1–3 of the KCNK2 gene. The vector was designed to allow
CRE-mediated deletion of exon 3, which encodes the TM1 domain
of the channel. The first loxp sequence was inserted in the 50
flanking intron of exon 3. Similarly, the PGK-neomycin resistance
cassette (neo) was inserted together with a second loxp sequence in
the 30 flanking intron of exon 3. Both loxp sequences were in the
same orientation to allow CRE-mediated simultaneous excision of
Exon 3 and neo cassette. A copy of the diphteric toxin gene was
subcloned adjacent to the homologous region for negative selection
of the ES clone. The targeting vector (50mg) was linearized prior to
electroporation into 129-derived embryonic stem cells. After drug
selection (G-418, 350 mg/ml), one positive clone (1/288) was
identified by Southern blot and PCR analysis. Five highly chimeric
males were generated by injection of the targeted ES cells into
C57Bl/6J blastocysts. They were mated with C57Bl/6J females and
germline transmission was assessed by Southern blot and PCR
analysis of tail DNA from the agouti pups. TREK-1 floxed mice were
then crossed with mice carrying the CRE recombinase gene under
the control of the ubiquitous CMV promoter (D Metzger).
Heterozygous TREK-1-deficient mice were then backcrossed with
C57Bl/6J congenic mice over 11 generations. All animals (þ /þ
and /) were 8- to 10-week-old males of N6F2 to N11F2 backcross
generation.
Kainate and pentylenetetrazol administration
After intraperitoneal injection of KA at 22 or 28 mg/kg, mice (n¼ 20
per group) were monitored for 2 h for onset and extent of seizures.
Seizure severity was blindly scored (Tsirka et al, 1995). PTZ was
injected similarly at 40 or 55 mg/kg and seizures were scored based
on the highest degree of seizure within 15 min of the PTZ injection.
The seizure index was calculated by averaging the points for seizure
activity in each group (n¼ 20 per genotype and treatment). EEGs
were recorded for 2 h on conscious mice (n¼ 10 per genotype
and treatment) using four small platinum electrodes (diameter
0.28 mm) placed in the hippocampus (1.2 mm lateral, 1.6 mm
posterior to the bregma, 1.6 mm inside) and in the anterior
neocortex (2 mm lateral, 0.5 mm anterior to the bregma, 1.5 mm
inside). The signals were amplified, digitized and quantified using
the Galileo system (Sirius BB, Medical Equipment International).
Forebrain ischemia model (2 VOþhypotension)
Global ischemia (n¼ 20 per genotype and treatment) was induced
by occluding both CCAs with aneurysm clips (Aesculap, Germany)
during a 30 min episode of systemic hypotension induced by
withdrawal of blood to maintain an MABP of 3073 mmHg (Sheng
et al, 1999).
Spinal cord ischemia model
Mice were subjected to crossclamping of the aortic arch, left
subclavian artery and internal mammary artery for 10 min (Lang-
Lazdunski et al, 2000). Motor function was blindly evaluated in the
hind limbs using a rating scale of 0 (normal function) to 6 (total
absence of movement) (Lang-Lazdunski et al, 2000).
Behavioral studies of sensitivity to anesthetic agents
Loss of righting reflex. Unrestrained mice (n¼ 10 per genotype
and volatile anesthetic) were placed in a chamber maintained at
33–351C. Carbon dioxide pressure (o0.05 atm) and rectal tempera-
ture (36.571.21C) were controlled. Each volatile anesthetic (chloro-
form, halothane, isoflurane, sevoflurane and desflurane) was
administered with a calibrated vaporizer in 100% oxygen as the
carrier gas with a fresh gas flow of 2 l/min at initial concentrations
of 3.0, 1.2, 1.0, 1.8 and 5%, respectively. Concentrations of the
volatile anesthetic were continuously measured by using a
calibrated infrared analyzer (RGM 5250, Ohmeda, Louisville). After
equilibration for 20 min at each initial anesthetic concentration,
mice were blindly scored for LORR. The concentration of the
anesthetics was then decreased in 10–20% increments and allowed
to re-equilibrate at each concentration. Mice were observed
continuously for recovery of the righting reflex. The concentration
reported for LORR was calculated by averaging the two concentra-
tions at which the mouse either retained or lost the righting reflex.
Data were reported as mean7s.e.m. Differences were evaluated
using an unpaired t-test.
Tail-clamp/withdrawal assay. MAC was determined using the tail-
clamp technique (Quasha et al, 1980). Mice (n¼ 20 per genotype
and volatile agent) were first exposed for 20 min to a constant
anesthetic concentration of almost 50% anesthetic induction values
used in clinical practice. A hemostatic clamp was applied for 45 s to
the midportion of the tail. Mice were scored blind for a motor
withdrawal in response to clamping the tail. A mouse was
considered to have moved if it made a purposeful muscular
movement of the hind limb and/or the body. The anesthetic
concentration was decreased in steps of 0.1% for each anesthetic,
and the testing sequence was repeated after 20 min of exposure to
each concentration. Concentration–response data were fitted to a
logistic equation, yielding half-effect concentrations (median MAC
values), slopes and estimates of their respective standard errors.
Median MAC values were given with their respective 95%
confidence interval limits. All P-values were two-tailed, and a
P-value o0.05 was considered significant.
Sleep time assay (i.e. duration of the LORR). Mice (n¼ 20 per
genotype and anesthetic agent) were blindly tested for the duration
of LORR (i.e. sleep time) in response to an intraperitoneal injection
of pentobarbital (30 mg/kg). Mean sleep times for each agent were
compared in null allele and wild-type mice using an unpaired t-test.
Onset of volatile and intravenous anesthetic action (i.e. latency to
the LORR). Mice (n¼ 10 per genotype and anesthetic agent) were
exposed to 8% chloroform, 4% halothane, 8% sevoflurane, 3%
isoflurane or 10% desflurane in the same chamber used for LORR
and tail-clamp assays. Onset of anesthetic action was defined as the
time interval between the beginning of the anesthetic inhalation or
the injection of the intravenous agent and the LORR.
Table II Respiratory rate (beats/min) of wild-type and TREK-1-deficient mice before the induction of anesthesia and at the MAC value
Chloroform Halothane Isoflurane Sevoflurane Desflurane
Wild-type preanesthesia 15274 16071 15972 15573 16371
Wild-type MAC 16674 14172 8474 10573 10673
Knockout preanesthesia 15472 15672 16172 15273 16072
Knockout MAC 17473 14874 9675 11673 11173
Data were expressed as mean7s.e.m. Statistical significance between wild-type and knockout mice was set at Po0.05.
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Electrophysiology on COS cells
COS cells were seeded at a density of 20 000 cells per 35-mm dish
24 h before transfection. Cells were transiently transfected by the
classical DEAE–dextran method with 0.1mg pCI-mTREK-1þ0.05mg
pCI-CD8. Transfected cells were visualized 48 h after transfection
using anti-CD8 beads. The external solution contained (in mM) 140
NaCl, 5 KCl, 2 MgCl2, 2 CaCl2 and 10 HEPES, adjusted to pH 7.4
with NaOH. The pipette solution contained (in mM) 140 KCl, 4
MgCl2, 5 EGTA and 10 HEPES (pH 7.2). The cell under study was
continuously superfused with a microperfusion system (0.1 ml/
min) at room temperature.
Electrophysiology on mouse striatal neurons
Primary culture of mouse striata was carried out according to Weiss
et al (1986). Cells were plated in culture dishes previously coated
with polyornithin and 50% fetal calf serum. Culture medium was
DMEM plus glucose (1.5 g/l) for the first 24 h, then B27 plus uridine
(2 mM) and 5-fluoro-20-deoxyuridine (2mM). Patch clamp measure-
ments were performed 2 or 3 days after plating. In outside-out
configuration, the internal solution contained (in mM) 155 KCl, 3
MgCl2, 5 EGTA, 10 HEPES and 5 ATP-K
þ (pH 7.2) and the external
solution contained (in mM) 120 NaCl, 5 KCl, 3 MgCl2, 1 CaCl2, and
10 HEPES. We daily prepared and added to the external solutions
10 mM tetra-ethyl-ammonium chloride, 3 mM 4-aminopyridine,
10 mM glibenclamide and 5 mM glucose (pH at 7.4). TREK current
anesthetic sensitivity was assessed in striatal neurons and in TREK-
1-expressing COS cells (Patel et al, 1999).
DNA extraction
Tail biopsy was lysed with proteinase K (200mg/ml) for 5–12 h at
561C in buffer containing 100 mM Tris (pH 8.5), 200 mM NaCl,
5 mM EDTA and 0.2% SDS. Proteinase K was heat inactivated at
951C for 5–10 min and the lysate was then either diluted in water for
PCR amplification or centrifuged to get rid of undigested material
prior to ethanol precipitation for subsequent digestion by restriction
enzymes.
Southern blot
For Southern blotting, genomic DNA was digested overnight with
the appropriate restriction enzyme, precipitated, size fractionated
on a 0.6% agarose gel and transferred onto a nylon membrane in
0.4 M NaOH. 32P-labelled probe hybridization was carried out
overnight at 651C in 0.5 M Na2Pi/5% SDS, pH 6.8.
PCR analysis
PCR reactions were performed on 1 ml of a 20–30 times water
dilution of the crude tail lysate in 15ml final volume containing
67 mM Tris–HCl (pH 8.8), 16 mM (NH4)2SO4, 0.01% Tween 20,
1.5 mM MgCl2, 200 mM dNTP and 0.2 ml Taq polymerase (Eurobio).
Conditions were as follows: for TREK-1, 941C/3 minb(941C/
20 sb581C/20 sb721C/35 s) 33, oligos (see Figure 1) #1 (50GGT
GCC AGG TAT GAA TAG AG30), #2 (50TTC TGA GCA GCA GAC TTG
G30), #3 (50GTG TGA CTG GGA ATA AGA GG30); for TRAAK, 941C/
3 minb(941C/30 s463.51C/25 s4721C/35 s) 35, primers #1
(50CCCTGCTCCTTCTTCCC30), #2 (30ATTCTTCCTTCCTCCCTTCC50),
#3 (50TGGACGAAGAGCATCAGGG30), #4 (50GAGGAGCAGCCAACTT
TAGC30) (see Supplementary Figure 1).
In situ hybridization
Perfused brain sections were hybridized with specific oligonucleo-
tide 30-end-labelled probes (nucleotides 726–694 and 1536–1504 of
the cloned mouse TREK-1; GenBank accesssion number U73488.2).
Immunohistochemistry
Immunostainings were performed on floating brain sections
(50mm) using the anti-rabbit a-TREK-1 (Lauritzen et al, 2000) and
c-fos (Oncogene) rabbit polyclonal antibodies. Sections were floated
in a solution of the primary antibody overnight at 41C (1:200
dilution). Biotinylated secondary antibodies were amplified using
a rabbit IgG Vector Elite ABC kit (Vector laboratories) with
3-diaminobenzidine as substrate.
TaqMan assays (real-time quantitative RT–PCR analysis)
Total RNA from the brain and cerebellum of Trek1/ and Trek1þ /þ
mice was isolated by using the Trizol method (InVitrogen). Reverse
transcription was performed with 2mg of total RNAs, treated for
30 min with RQ1 DNase I (Promega) and reverse-transcribed with
Superscript II reverse transcriptase (InVitrogen). Real-time PCR
analysis (SYBR Green Mastermix Plus, Eurogentec) was performed
to estimate the level of expression of TREK-1, TREK-2, TRAAK,
TASK-1, TASK3, TWIK-1 and GABAa6 subunit in the brain and
cerebellum of Trek1/ and Trek1þ /þ mice. Primers for the seven
different amplicons were as follows:
TREK-1 forward TTTTCCTGGTGGTCGTCCTC;
TREK-1 reverse GCTGCTCCAATGCCTTGAAC;
TREK-2 forward CCGGAATTACTCTCTGGATGAAGA;
TREK-2 reverse CATGGCTGTGCTGGAGTTGT;
TRAAK forward CCCCAGTGAGAATCTGGCC;
TRAAK reverse GGGCACAGCCACGCTC;
TASK-1 forward CGGCTTCCGCAACGTCTAT;
TASK-1 reverse TTGTACCAGAGGCACGAGCA;
TASK-3 forward GACGCCCTCGAGTCGGACCA;
TASK-3 reverse CTCTGAGACGGACTTCTTC;
TWIK-1 forward TGTCCTTCTCCTCCGTCACTG;
TWIK-1 reverse AGGCCACAAAAGGCTCACTTT;
GABAa6 forward CGCCCCCTGTGGCAA;
GABAa6 reverse TACTTGGAGTCAGAATGCACAACA;
CYCLOPHILIN forward GGCTCTTGAAATGGACCCTTC;
CYCLOPHILIN reverse CAGCCAATGCTTGATCATATTCTT.
Real-time PCR assays for each gene target were performed on
cDNA samples in 96-well plates on an ABI Prism 7700 Sequence
Detection System (PE Biosystems). PCR data were captured using
Sequence Detector Software. Data were analyzed using the
comparative CT method where the amount of target was normal-
ized to an endogeneous reference (cyclophilin D) and calibrated to
the amount of target in wild-type mice (User Bulletin No. 2 Applied
Biosystems). Experiments were performed in triplicate. Standard
curves were generated for each set of primers using serial dilutions
of mouse brain cDNA to ensure a high efficiency of amplification.
Supplementary data
Supplementary data are available at The EMBO Journal Online.
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